WORLD

Vaccine For Children : WHO Adds Serum NovaVax CovoVax Vaccine To Emergency Use List Children Less Than 3 Years Old Can Be Vaccinated

Written by admin
[orginal_title]
Washington
The World Health Organization (WHO) on Friday added Kovovax, an anti-Covid vaccine manufactured by the Serum Institute of India (SII) under license from US pharmaceutical company Novavax, to its emergency use list. In this way the number of vaccines approved by the global health body has increased. SII Chief Executive Officer (CEO) Aadar Poonawalla described the WHO’s decision as ‘another milestone’ in the fight against COVID-19.

The World Health Organization said in a tweet on Friday, ‘WHO has added Kovovax to its emergency use list. This has increased the number of WHO validated vaccines against Kovid-19. This vaccine is manufactured by Serum Institute of India under license from Novavax. According to the WHO, Covovax was assessed on the basis of its emergency use inventory process based on a review of data on quality, safety and efficacy, risk management plan and vaccine manufacturing site inspections by the Drug Controller General of India (DCGI).

‘WHO’s decision is very important for the world’
In a joint statement, American pharmaceutical company Novavax and SII noted that the vaccine has been approved for vaccination of persons 18 years of age and older to prevent the coronavirus disease caused by SARS-CoV-2. “Today’s decision by WHO is important to ensure global access to a protein-based anti-COVID-19 vaccine for millions of people around the world,” said Stanley C. Erck, President and CEO of Novavax.

‘Another milestone in the fight against Kovid’
Poonawalla tweeted, ‘This is another milestone in our fight against COVID-19, Kovovax has now been approved for emergency use by WHO. This vaccine has shown excellent safety and efficacy. Thank you all for a great collaboration.’ SII is already manufacturing ‘Covishield’ vaccine in collaboration with pharmaceutical company AstraZeneca.

Children below the age of three will get protection
Earlier this week, Poonawalla said that SII plans to launch Kovovax in the next six months. He had said that ‘Kovovax’ will provide protection to children below the age of three, as the tests have shown great data. Kovovax is still awaiting emergency use approval from India’s drug regulator DCGI.

[title-words_as_hashtags]

About the author

admin

Leave a Comment